PUBLICATIONS
click for access
2011
Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, Muller WJ, Kremer R. (2011). PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy targets. J Clin Invest. Dec 1;121(12):4655-69.
Labelle-Côté M, Dusseault J, Ismaïl S, Picard-Cloutier A, Siegel PM, Larose L.(2011). Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo. BMC Cancer. Oct 12;11:443.
Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM. (2011). CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol. 2011 May;178(5):2377-88.
S. Tabariès, Z. Dong, M.G. Annis, A. Omeroglu, F. Pepin, V. Ouellet, C. Russo, M. Hassanain, P. Metrakos, Z. Diaz, M. Basik, N. Bertos, M. Park, C. Guettier, R. Adam, M. Hallett and P.M. Siegel (2011). Claudin-2 enhances integrin-mediated breast cancer cell adhesion and promotes liver metastasis. Oncogene 30, 1318-1328.
Y.He, J.J. Northey, M. Primeau, R.D. Machado, R. Trembath, P.M. Siegel and N. Lamarche-Vane (2011). CdGAP is required for Transforming Growth Factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Oncogene 30, 1032-1045
S. Hassan, M. Buchanan, L. Gaboury, W. Muller, A. Alsawafi, A. Mourskaia, P. Siegel and M. Basik. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J Cancer, 129:1, 225–232.
2010
A. Bemmo, C. Dias, A.A.N. Rose, C. Russo, P. Siegel and J. Majewski. (2010). Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS One 5(8). pii: e11981.
M. Demers, A.A.N. Rose, A.A. Grosset, L. Gaboury, P.M. Siegel, Y. St-Pierre. (2010) Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am. J. Path. 176(6):3023-3031.
A.A.N. Rose, P.A. MacDonald, Z. Dong, C. Russo, N.R. Bertos, R. Simantov, M. Park and P.M. Siegel (2010). GPNMB/Osteoactivin is an independent prognostic indicator of recurrence and a potential therapeutic target in breast cancer. Clin. Cancer Res. 16(7): 2147-2156.
P.M. Siegel and W.J. Muller (2010). Transcription Factor Regulatory Networks in Mammary Epithelial Development and Tumorigenesis. Oncogene. 29(19):2753-2759.
A.A. Rose and P.M. Siegel (2010). Emerging Therapeutic Targets in Breast Cancer Bone Metastasis. Future Oncology 6(1):55-74.
2009
K. Tiedemann, O. Hussein, G. Sadvakassova, Y. Guo, P.M. Siegel, and S.V. Komarova. (2009). Breast cancer derived factors stimulate osteoclastogenesis through synergy between the Ca2+/PKC and TGFbeta/MAPK signaling pathways. J. Biol. Chem. 284(48):33662-33670.
Kristin Roovers, Simona Wagner, Christopher J. Storbeck, Paul O’Reilly, Jason Northey, Juliann Chmielecki, William J. Muller, Peter M. Siegel and Luc A. Sabourin (2009). The Ste20-like kinase SLK is required for ErbB2-driven motility of mammary epithelial cells. Oncogene 28(31):2839-2848.
Dydensborg, AB, Rose, AAN, Grote, D, Paquet, M, Siegel, PM and Bouchard, M. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis independently of its effects on cell differentiation. Oncogene 28(29): 2634-2642.
A.A. Mourskaia, Z. Dong, S. Ng, M. Banville, J. Zwaagstra, M. O'Connor-McCourt, P.M. Siegel. (2009). Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene. 28:1005-15.
Previous
J.J. Northey, J. Chmielecki, E. Ngan, C. Russo, M.G. Annis, W. J. Muller, P.M. Siegel. (2008). Signaling through ShcA is required for TGF-beta and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol. Cell Biol. 28(10):3162-76.
A.A.N. Rose, F. Pepin, C. Russo, J.E. Abou Khalil, M. Hallet, P.M. Siegel. (2007). Osteoactivin Promotes Breast Cancer Metastasis to Bone. Mol. Cancer Res. 5(10):1001-14.
A.A. Mourskaia, J.J.Northey, P.M. Siegel. (2007). Targeting aberrant TGF-β signaling in pre-clinical models of cancer. Anticancer Agents Med.Chem. 7(5):504-514
A.A.N. Rose and P.M. Siegel. (2006). Breast Cancer-Derived Factors Facilitate Osteolytic Bone Metastasis. Bull. Cancer. 93(9): 931-943
G.P. Gupta, A.J. Minn, Y. Kang, P.M. Siegel, I. Serganova, C. Cordon-Cardo, A.B. Olshen, W.L. Gerald and J. Massague (2005). Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harb Symp Quant Biol. 70:1-10.
A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos , W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald and J. Massagué. (2005). Genes that mediate breast cancer metastasis to lung. Nature. 436: 518-524.
P.M. Siegel and J. Massagué. (2003). Cytostatic and apoptotic actions of TGF-b in homeostasis and cancer. Nat. Rev. Cancer. 3: 807-820.
P.M. Siegel, W. Shu and J. Massagué. (2003). Mad Upregulation and Id2 Repression Accompany TGF-b Mediated Epithelial Cell Growth Suppression. J. Biol. Chem. 278: 35444-35450.
P.M. Siegel, W. Shu, R.D. Cardiff, W.J. Muller and J. Massagué. (2003). Transforming Growth Factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA. 100: 8430-8435.
Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cardon-Cardo, T.A. Guise and J. Massagué. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3: 537-549.
C-R. Chen, Y. Kang, P.M. Siegel and J. Massagué. (2002). E2F4/5 and p107 as Smad Cofactors linking the TGFb Receptor to c-myc repression. Cell 110: 19-32.
::